<img src="https://ml.globenewswire.com/Resource/Download/aceda01c-bc94-4579-88fa-c0294406b49f?size=2" nborder="0" align="left" hspace="5" vspace="5" title="NuvectisPharma_Logos_FINAL_Full_Color.png" alt="Nuvectis Pharma, Inc."/>Fort Lee, NJ, May 14, 2026 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced that management will participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ on Tuesday, May 19, 2026 in New York. Conference Details: Date: Tuesday, May 19, 2026 Company Presentation: 9:00 – 9:30AM EDT Presenter: Ron Bentsur, Chairman and Chief Executive Officer of Nuvectis Webcast Link: <a href="https://www.globenewswire.com/Tracker?data=KFprPYTeCetfhkQuA6hCqmxfRM5HUH6X4-TePkAe9uVJSyZv2_GJPGfe7B64sl6naO9oeD5_JHjhyUGzKkREarDmnsg0i3Izvt9Qac_p4f23Y0HoRTh3a6CW8gIQ1F8XtuNgEml0WJSXHYg8CCDyQQ==" rel="nofollow" target="_blank" title="here">here</a> Location: New York, NY A webcast of the presentation will be available in the Investors section of Nuvectis’ website at <a href="https://www.globenewswire.com/Tracker?data=HCja_7288itmFT2dfsPlkP1UD2p31cMyk_kiGi3bah79ZjjYUipWdJWXoS2epX3HdtIzDKnkzmS6pa2mrM9OttbIiSNXrY2-yMo1qdrdsSo=" rel="nofollow" target="_blank" title="www.nuvectis.com">www.nuvectis.com</a>. About Nuvectis Pharma, Inc. Nuvectis Pharma, Inc. is a biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology. The Company is developing NXP900, a clinical-stage drug candidate. NXP900 is an oral small molecule inhibitor of the SRC Family of Kinases (SFK), including SRC and YES1. Its unique mechanism of action enables inhibition of both the catalytic and scaffolding functions of the SRC kinase, providing comprehensive shutdown of the signaling pathway. NXP900 has completed a Phase 1a dose escalation study, a drug-drug interaction study in healthy volunteers and the Phase 1b program is ongoing. Company Contact: Ron Bentsur Chairman, Chief Executive Officer and President <a href="https://www.globenewswire.com/Tracker?data=w9KV7BCdFKNcPMytpUG_uAvx28dwMTMRI_wgRcm81IMbkAtZiWE4OCsmUp-mw2KhGC7jIzEG6ymGYrSOBC9DnX1__lbSoB910znM82KRpYM=" rel="nofollow" target="_blank" title="rbentsur@nuvectis.com">rbentsur@nuvectis.com</a> Media Relations Contact: Kevin Gardner LifeSci Advisors <a href="https://www.globenewswire.com/Tracker?data=2f2YvFyA6scN3pwWURVsuaAQiJ0Mqu_JblEqv70MtB3BXunU6cyPiz2EDlAunYIxGj_r4QlEjX-MDaG0sC-TXWJT8XrzUiRN9FVZ7RVXeBbq8FZ8-GKKdN0p-Na6ZEuu" rel="nofollow" target="_blank" title="kgardner@lifesciadvisors.com">kgardner@lifesciadvisors.com</a> <img alt="" src='https://ml.globenewswire.com/media/ZjJmODMwYWUtNWMwZC00ZWMxLWEwYTQtNGI4OWM0MDM1NTY0LTUwMDA4MjgxNy0yMDI2LTA1LTE0LWVu/tiny/Nuvectis-Pharma-Inc-.png' referrerpolicy='no-referrer-when-downgrade' />

GlobeNewswire Inc.

Nuvectis Pharma, Inc. To Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ

Latest news from the world of business and finance – both local and global

MONEY FM 89.3 is Singapore's first and only Business and Personal Finance station, featuring local and international business and financial news.

MONEY FM 89.3

Discover newsletters from our DJs on LinkedIn